The Valley Desk

ArticleClinical epigeneticsPublished

MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Cooper Medical School of Rowan University, Coriell Institute for Medical Research, Lewis Katz School of Medicine, Rowan University, Temple University. Affiliation source

Publication record

Type
Article
Venue
Clinical epigenetics
Published
Subject terms
Cell Line, Tumor; Animals; Humans; Mice; Rats; Apoptosis; DNA Methylation; Cyclin-Dependent Kinase 9; Leukemia, Myeloid, Acute; Decitabine; CDK9; Epigenetic Therapy
PubMed ID
38172923
PubMed Central ID
PMC10765884
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal